title: Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy.
abstract: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in France, we analysed clinical, biological and pathological data of 27 patients with SPTCL. Medical history revealed that 40% of patients had been previously diagnosed with an autoimmune disorder and 22% with inflammatory panniculitis. Haemophagocytic syndrome was present in 37% of cases. Autoantibodies were positive in 65% of cases. Complete remission (CR) was reached in 74% of cases. Immunosuppressive drug treatment was given in 69.5% of patients (group 1) and polychemotherapy in 30.5% (group 2). CR was 81.2% and 28.5% (p?=?0.025), respectively. Progression rate was 6.2% and 42.8% (p?=?0.067), respectively. This study suggests that immunosuppressive drugs should be considered as the first-line treatment for SPTCL.
authors.affiliation: Service d'anatomie pathologique, Hôpital Necker-Enfants Malades, Paris, APHP, Université Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: David
authors.initials: D
authors.lastname: Michonneau
authors.forename: Tony
authors.initials: T
authors.lastname: Petrella
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ortonne
authors.forename: Saskia
authors.initials: S
authors.lastname: Ingen-Housz-Oro
authors.forename: Nathalie
authors.initials: N
authors.lastname: Franck
authors.forename: Stéphane
authors.initials: S
authors.lastname: Barete
authors.forename: Maxime
authors.initials: M
authors.lastname: Battistella
authors.forename: Marie
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: Béatrice
authors.initials: B
authors.lastname: Vergier
authors.forename: Marc
authors.initials: M
authors.lastname: Maynadié
authors.forename: Christine
authors.initials: C
authors.lastname: Bodemer
authors.forename: Olivier
authors.initials: O
authors.lastname: Hermine
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.forename: Nicole
authors.initials: N
authors.lastname: Brousse
authors.forename: Sylvie
authors.initials: S
authors.lastname: Fraitag
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015434:Panniculitis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016016:Proportional Hazards Models; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents